Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Public ClinicalTrials.gov record NCT04704219. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants With First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (nccRCC) (KEYNOTE-B61)
Study identification
- NCT ID
- NCT04704219
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 160 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- Lenvatinib Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 22, 2021
- Primary completion
- Jan 26, 2025
- Completion
- Oct 20, 2025
- Last update posted
- Dec 2, 2025
2021 – 2025
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Georgetown University Medical Center ( Site 0001) | Washington D.C. | District of Columbia | 20007 | — |
| St. Vincent Frontier Cancer Center ( Site 0004) | Billings | Montana | 59102 | — |
| Comprehensive Cancer Centers of Nevada ( Site 0010) | Las Vegas | Nevada | 89169 | — |
| Memorial Sloan Kettering Cancer Center ( Site 0015) | New York | New York | 10065 | — |
| Fox Chase Cancer Center ( Site 0011) | Philadelphia | Pennsylvania | 19111 | — |
| Vanderbilt University Medical Center ( Site 0008) | Nashville | Tennessee | 37232 | — |
| Seattle Cancer Care Alliance ( Site 0014) | Seattle | Washington | 98109 | — |
| MEDICAL COLLEGE OF WISCONSIN ( Site 0006) | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04704219, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04704219 live on ClinicalTrials.gov.